Haleon (HLN) revenue breakdown
By segment, EMEA & LatAm is the largest at 42% of fiscal 2025 revenue; APAC grew fastest, 5% a year over 5 years.
By product, Oral Health is the largest at 31% of fiscal 2025 revenue; Respiratory Health grew fastest, 8% a year over 5 years.
Revenue by segment
Fiscal years, as Haleon reports them in its 10-K filings; fiscal 2025 total $11.0B.
| Segments | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| EMEA & LatAm | $4.1B | $3.9B | $4.3B | $4.5B | $4.6B | $4.6B | 42% |
| North America | $3.8B | $3.5B | $4.1B | $4.2B | $4.0B | $3.9B | 35% |
| APAC | $2.1B | $2.1B | $2.5B | $2.6B | $2.6B | $2.6B | 23% |
Revenue by product
Fiscal years, as Haleon reports them in its 10-K filings; fiscal 2025 total $11.0B.
| Products | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Oral Health | $2.7B | $2.7B | $3.0B | $3.1B | $3.3B | $3.5B | 31% |
| Pain Relief | $2.2B | $2.2B | $2.6B | $2.7B | $2.6B | $2.6B | 23% |
| Respiratory Health | $1.3B | $1.1B | $1.6B | $2.2B | $2.1B | $1.9B | 17% |
| Vitamins, Minerals and Supplements | $1.5B | $1.5B | $1.7B | $1.6B | $1.7B | $1.7B | 15% |
| Digestive Health | — | — | — | $1.0B | $1.0B | $987M | 9% |
| Therapeutic Skin Health and Other | — | — | — | $618M | $510M | $460M | 4% |
| Digestive Health and Other | $2.2B | $2.0B | $2.1B | — | — | — | — |
Revenue by region
Fiscal years, as Haleon reports them in its 10-K filings; fiscal 2024 total $11.2B.
| Regions | 2020 | 2021 | 2022 | 2023 | 2024 | Share |
|---|---|---|---|---|---|---|
| Rest of World | $5.4B | $5.2B | $5.9B | $6.2B | $6.2B | 56% |
| US | $3.4B | $3.2B | $3.7B | $3.8B | $3.6B | 32% |
| China | $700M | $801M | $907M | $966M | $987M | 9% |
| UK | $374M | $327M | $348M | $381M | $384M | 3% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for HLN.
Open HLN in InvestinglyQuestions
Where does Haleon make its money?
In fiscal 2025, by segment: EMEA & LatAm $4.6B, North America $3.9B, APAC $2.6B.
From Haleon's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.